1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO PROSPECTIVO, DE UN SOLO BRAZO Y EN ENTORNO CLÍNICO PARA DESCRIBIR LA EFICACIA, TOLERABILIDAD Y COMODIDAD DEL TRATAMIENTO CON TERIFLUNOMIDA UTILIZANDO RESULTADOS NOTIFICADOS POR EL PACIENTE (PATIENT REPORTED OUTCOMES, PRO) EN PACIENTES CON ESCLEROS IS MÚLTIPLE RECIDIVANTE (EMR).

ESTUDIO PROSPECTIVO, DE UN SOLO BRAZO Y EN ENTORNO CLÍNICO PARA DESCRIBIR LA EFICACIA, TOLERABILIDAD Y COMODIDAD DEL TRATAMIENTO CON TERIFLUNOMIDA UTILIZANDO RESULTADOS NOTIFICADOS POR EL PACIENTE (PATIENT REPORTED OUTCOMES, PRO) EN PACIENTES CON ESCLEROS IS MÚLTIPLE RECIDIVANTE (EMR).

Datos básicos

Código:
LPS13567
Protocolo:
LPS13567
EUDRACT:
2013-001439-34
NCT:
Centro:
Dotación:
Año de incio:
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

GENZYME CORPORATION

Resultados del Ensayo Clínico

[Farewell open letter to SEFH members].

Poveda Andrés JL

Editorial Material. 10.7399/fh.2015.39.6.10128. 2015


[Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)].

Fernández Ó; (...); Grupo Post-ECTRIMS

Article. 10.33588/rn.5907.2014334. 2014


[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A guide to treating gait impairment with prolonged-release fampridine (Fampyra (R)) in patients with multiple sclerosis

Ramio-Torrenta, L; (...); Saiz, A

Review. 10.1016/j.nrl.7015.11.013. 2018

  • Open Access.

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020


A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018


A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020


A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Article. 10.1038/tpj.2015.80. 2016


Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Aflibercept in exudative age related macular degeneration refractory to ranibizumab.

Ruiz Ramos J; (...); Gallego-Pinazo R

Article. 10.1016/j.oftal.2015.07.018. 2015


An algorithm to predict intrathecal synthesis of IgG with high efficiency

Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura

Meeting Abstract. 2023


An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.

Bracher A; (...); Dornmair K

Article. 10.1002/acn3.50974. 2020


Analisis de las causas de suspension de tratamiento con triple terapia antiviral en pacientes con hepatitis C.

Ruiz Ramos J; (...); Poveda Andrés JL

Abstract of Published Item. 10.7399/fh.2014.38.3.1171. 2014


Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


Anidulafungin-Induced Alopecia

Ruiz-Ramos J; (...); Poveda-Andrés JL

Article. 10.1177/1060028014524534. 2014


Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

Höftberger R; (...); Saiz A

Article. 10.1177/1352458514555785. 2015


Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab

Villar, L.; (...); Alvarez-Cermeno, J. C.

Article. 2013


Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023


Assessment of the quality of sample labelling for clinical research.

Pérez-Huertas P; (...); Poveda-Andrés JL

Article. 10.7399/fh.2016.40.2.9753. 2016


Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

Espiño M; (...); Villar LM

Article. 10.1016/j.cca.2014.08.004. 2015


Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

Lunemann JD; (...); Comabella M

Article. 10.1212/NXI.0000000000200270. 2024


Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

Monreal, Enric; (...); Villar LM

Article. 10.1001/jamaneurol.2023.0010. 2023


Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation

Sánchez-Lázaro I; (...); Aliño SF

Article. 10.2217/pgs.15.39. 2015


Atypical periodic alternating nystagmus responding to high-dose intravenous immunoglobulins: a case report

Argente-Escrig, H; (...); Casanova Estruch B

Article. 10.1186/s12974-017-0846-1. 2017


Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Burman, J; (...); Farge, D

Article. 10.1038/bmt.2017.40. 2017


Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.

Boix Lago, A.; (...); Casanova Estruch, B.

Meeting Abstract. 2023


Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-017-2933-6. 2017


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2021


Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients

Mathur, D; (...); Lopez-Rodas, G

Article. 10.3389/fncel.2017.00209. 2017


Biomarkers in multiple sclerosis: an update for 2014

Fernandez O; (...); Montalban X

Review. 10.33588/rn.5812.2014247. 2014


Biosimilares: viejas polemicas con nuevos argumentos.

Poveda-Andrés JL, Bosó-Ribelles V

Editorial Material. 10.7399/fh.2015.39.3.8978. 2015


BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017


Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies

Navarro Canto, L.; (...); Casanova Estruch, B.

Meeting Abstract. 2019


Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype

Canto, LN; (...); Estruch, BC

Article. 10.3389/fneur.2019.01157. 2019


Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura

Article. 10.1002/brb3.2044. 2021


Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017


Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects

Mathur D; (...); Burgal-Marti M

Article. 10.3389/fncel.2015.00375. 2015


Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 2015


Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.

Quintanilla-Bordás C; (...); Casanova B

Article. 10.3389/fneur.2022.897275. 2022


Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis

Gil-Perotin, S.; (...); Casanova, B.

Meeting Abstract. 2021


Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study

Lacruz-Ballester, L.; (...); Casanova-Estruch, B.

Meeting Abstract. 2021


Circulating mirna signatures in PPMS

Martin, MMS; (...); Torrenta, LRI

Meeting Abstract. 2020


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Oreja-Guevara, Celia; (...); Rio, Jordi

Article. 10.1016/j.msard.2024.105787. 2024


Clinical evaluation of rituximab treatment for neuromyelitis optica

Fernández-Megía MJ; (...); Poveda-Andrés JL

Article. 10.1016/j.nrl.2014.09.001. 2015


Clinical experience with rituximab in the treatment of refractory multiple sclerosis

Gascon, F.; (...); Coret, F.

Meeting Abstract. 2014


Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014


Clinical impact of early brain atrophy in clinically isolated syndromes.

Pérez-Miralles F; (...); Montalban X

Article. 10.1177/1352458513488231. 2013


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019


Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024


Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab

Toboso, I; (...); Villar, LM

Meeting Abstract. 2017


Cognitive impairment in multiple sclerosis: diagnosis and monitoring.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-021-05165-7. 2021


Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Lopez-Soley, Elisabet; (...); Solana, Elisabeth

Meeting Abstract. 2022

  • Open Access.

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.

Lopez-Soley E; (...); Solana E

Article. 10.3390/jpm12050743. 2022


Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Gil-Perotin S; (...); Casanova B

Article. 10.3389/fneur.2019.01008. 2019


Comorbilidad en esclerosis multiple y su abordaje asistencial.

Estruch BC

Abstract of Published Item. 10.1016/S0025-7753(15)30004-X. 2014


Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024


Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Consensus document on spasticity in patients with multiple sclerosis

Oreja-Guevara, Celia; (...); Fernandez, Oscar

Article. 10.33588/rn.5708.2013374. 2013


Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.

Medina-Polo J; (...); López-Fando L

Article. 10.1002/nau.24276. 2020


Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Consensus on early detection of disease progression in patients with multiple sclerosis

Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia

Article. 10.3389/fneur.2022.931014. 2022


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017


Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020


COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018


Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice

Lorente-Fernandez, L; (...); Poveda-Andres, JL

Article. 10.1136/ejhpharm-2013-000426. 2015


COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.

Brändle SM; (...); Dornmair K

Article. 10.1073/pnas.1916337118. 2021


Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019


CSF chitinase 3-like-1 association with disability of primary progressive MS

Perez-Miralles, F; (...); Casanova, B

Article. 10.1212/NXI.0000000000000815. 2020


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Cytokines profile in the cerebrospinal fluid in chronic relapsing inflammatory demyelinating diseases of the central nervous system

Simo-Castello, M.; (...); Coret, F.

Meeting Abstract. 2014


Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients

Miralles, FP; (...); Casanova, B

Meeting Abstract. 2019


Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis

Izquierdo Ayuso, G.; (...); Casanova Estruch, B.

Meeting Abstract. 2021


Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2018


Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.

Balzano T; (...); Felipo V

Article. 10.1016/j.jhep.2019.01.008. 2020


Daclizumab in multiple sclerosis.

Perez-Miralles, FC

Review. 10.33588/rn.6608.2018083. 2018


Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Deciphering Multiple Sclerosis Progression.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos

Review. 10.3389/fneur.2021.608491. 2021


Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018


Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade

Ribes García S; (...); Casanova Estruch B

Article. 10.1159/000446580. 2016


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.

Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura

Article. 10.1159/000519772. 2022


Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019


DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-018-3442-y. 2018


DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Brieva, Luis; (...); Moral, Ester

Article. 10.1016/j.msard.2022.103805. 2022


Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects

Mathur, D; (...); Burgal-Marti, M

Article. 10.3390/brainsci8010001. 2018


Documento de consenso sobre la espasticidad en pacientes con esclerosis multiple.

Oreja-Guevara C; (...); Fernández Ó

Abstract of Published Item. 10.33588/rn.5708.2013374. 2013


Does benign multiple sclerosis exist?

Verdini Martinez, Laura; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.

Pérez Huertas P; (...); Poveda Andrés JL

Article. 10.7399/fh.2015.39.4.8839. 2015


Drug Interaction Between Oral Cyclosporine Modified and Iron

Domingo-Chiva, E; (...); Poveda-Andres, JL

Article. 10.1177/1060028013514734. 2014


Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study

Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1007/s13760-020-01516-x. 2020


Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023


Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.

Meca-Lallana, J E; (...); Calles Hernandez, C

Article. 10.1016/j.nrleng.2021.06.006. 2023


Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Meca-Lallana, J. E.; (...); Hernandez, C. Calles

Article. 10.1016/j.nrl.2021.06.007. 2024


Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Megias-Vericat, JE; (...); Poveda, JL

Review. 10.1007/s10072-017-2833-9. 2017


Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study

Oreja-Guevara, C.; (...); Meca-Lallana, J. E.

Meeting Abstract. 2021


ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA

Sole A; (...); Casado MA

Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014


Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018


Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Eculizumab for a catastrophic relapse in NMOSD: case report.

Gorriz, David; (...); Casanova, Bonaventura

Article. 10.1007/s10072-023-06971-x. 2023


Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020


EFFECT OF CYP3A5 GENOTYPE ON TACROLIMUS DOSE REQUIREMENT, NEPHROTOXICITY AND ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Rojas, L.; (...); Alino, S. F.

Article. 2013


Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

Rojas L; (...); Aliño SF

Article. 10.1038/tpj.2014.38. 2015


Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Meca-Lallana JE; (...); Llarena C

Article. 10.1007/s40120-023-00557-7. 2023


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Alcala, Carmen; (...); Casanova, Bonaventura

Article. 10.1007/s00415-022-10989-0. 2022


Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P; (...); NeuroAdvan study

Article. 10.1212/NXI.0000000000000147. 2015


EFFECTS OF POLYMORPHIMS OF CYP3A5 AND ABCB1 GENES ON CHRONIC NEPHROPATHY: COHORT STUDY

Rojas, L.; (...); Alino, S. F.

Article. 2013


Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Alcala, C; (...); Casanova, B

Article. 10.1007/s00415-018-8899-3. 2018


eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018


Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018


Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Quintanilla-Bordás C; (...); Pérez-Miralles FC

Case Reports. 10.3389/fimmu.2024.1465678. 2024


Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA(A) receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies

Petit-Pedrol M; (...); Dalmau J

Article. 10.1016/S1474-4422(13)70299-0. 2014


Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco

Article. 10.3390/jpm12010119. 2022


Estudio de utilizacion de boceprevir y telaprevir para el tratamiento de la hepatitis C cronica.

Marrero-Álvarez P; (...); Poveda-Andrés JL

Abstract of Published Item. 10.7399/FH.2014.38.1.1128. 2014


EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024


Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 10.1016/j.gastrohep.2014.05.004. 2014


Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017


EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY

Paz S; (...); Urcelay J

Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015


Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Fingolimod plus steroids prevents return to clinical activity after natalizumab withdrawal

Alcala, C.; (...); Casanova, B.

Article. 2013


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

Bosó V; (...); Aliño SF

Article. 10.1097/FTD.0b013e3182a94e65. 2014


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018


Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.

Castillo-Villalba, Jessica; (...); Casanova, Bonaventura

Article. 10.3389/fimmu.2022.827738. 2022


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

Zubizarreta, I; (...); Villoslada, P

Article. 10.1073/pnas.1820039116. 2019


Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension

Zubizarreta, I; (...); Villoslada, P

Meeting Abstract. 2019


Immunoglobulin M Oligoclonal Bands: Biomarker of Targetable Inflammation in Primary Progressive Multiple Sclerosis

Villar LM; (...); Bar-Or A

Article. 10.1002/ana.24190. 2014


Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017


Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017


IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

  • Open Access.

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017


Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018


Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study

Meca-Lallana, Jose E.; (...); Maurino, Jorge

Article. 10.1007/s40120-022-00356-6. 2022


Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective

Meca-Lallana, Jose; (...); Maurino, Jorge

Meeting Abstract. 10.1016/j.jns.2021.118844. 2021


Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017


Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ruiz J; (...); Aliño SF

Article. 10.3390/ijms160920168. 2015


Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020


Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018


Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study

Meca Lallana, Jose; (...); Forner, Mireia

Meeting Abstract. 10.1212/WNL.0000000000202381. 2023


Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo

Article. 10.1186/s41687-024-00822-9. 2024


Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2023.104997. 2023


In Situ RT-PCR Optimized For Electron Microscopy Allows Description Of Subcellular Morphology Of Target mRNA-Expressing Cells In the Brain

LAURA CUBAS NÚÑEZ; (...); Gil-Perotin S

Article. 2017

  • Open Access.

In situ RT-PCR Optimized for Electron Microscopy Allows Description of Subcellular Morphology of Target mRNA-Expressing Cells in the Brain

Cubas-Nunez, L; (...); Gil-Perotin, S

Article. 10.3389/fncel.2017.00141. 2017


Incompatibility of undiluted busulfan injection with a needle-free valve

Cueto-Sola, M; (...); Poveda-Andres, JL

Letter. 10.2146/ajhp140111. 2014


Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis

Comabella, Manuel; (...); Luenemann, Jan D.

Article. 10.1007/s00415-024-12763-w. 2025


Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018


Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016


Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015


Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019


Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017


Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016


Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019


Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation

Beltrán E; (...); Dornmair K

Article. 10.1093/brain/awu205. 2014


Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?

Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch

Article. 10.1016/j.msard.2023.105033. 2023


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


Leptomeningeal gadolinium enhancement in multiple sclerosis

Gascon-Gimenez, F; (...); Casanova, V

Meeting Abstract. 2019


Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures

Garcia, F; (...); Casanova, B

Meeting Abstract. 2018


Lipid-specific IgM oligoclonal bands in clinically isolated syndrome: 5-years follow-up

Molla, B.; (...); Casanova, B.

Meeting Abstract. 2014


Lipid-Specific Immunoglobulin M Bands in Cerebrospinal Fluid Are Associated with a Reduced Risk of Developing Progressive Multifocal Leukoencephalopathy during Treatment with Natalizumab

Villar LM; (...); Álvarez-Cermeño JC

Article. 10.1002/ana.24345. 2015


Lipid-specific oligoclonal IgM bands: is there any influence on the response to treatment with fingolimod?

Perez-Romero, L.; (...); Casanova, B.

Meeting Abstract. 2014


Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

Frasquet M; (...); Casanova B

Article. 10.1016/j.jneuroim.2013.07.003. 2013


Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience

Rubio Alcantud, Almudena; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis

Estruch, BC; (...); Coret, F

Meeting Abstract. 2017


Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1016/j.jns.2020.117180. 2020


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE; (...); Aliño SF

Article. 10.1097/FPC.0b013e3283642fb3. 2013


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

Garcia-Foncillas, J; (...); Gomez, MVP

Review. 10.1007/s40291-021-00544-4. 2021


miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis

Article. 10.1212/NXI.0000000000200069. 2023


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors

Haines JD; (...); Lopez-Rodas G

Article. 10.1177/1352458515573094. 2015


N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM

Climente Martí M, Poveda Andrés JL, Culebras J

Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.

Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura

Article. 10.1007/s10072-023-07252-3. 2023


Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus

Sepúlveda M; (...); Saiz A

Article. 10.1212/NXI.0000000000000225. 2016


New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Toboso I; (...); Villar LM

Article. 10.3389/fneur.2020.579438. 2020


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Alcala, C.; (...); Casanova, B.

Article. 10.1007/s00415-021-10926-7. 2022


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.

Alcala Vicente, Carmen; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2022.991596. 2022


Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity

Castillo, J.; (...); Casanova, B.

Meeting Abstract. 2022


Oligoclonal M bands unveil occult inflammation in multiple sclerosis.

Casanova B; (...); Pérez-Miralles F

Article. 10.1016/j.msard.2022.104118. 2022


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018


Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Coret F; (...); Casanova B

Article. 10.1177/2055217318783347. 2018


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Meca-Lallana, JE; (...); Maurino, J

Article. 10.2147/PPA.S305707. 2021


Perception of stigma in patients with primary progressive multiple sclerosis.

Pérez-Miralles F; (...); Casanova-Estruch B

Article. 10.1177/2055217319852717. 2019


Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)

Lallana, Jose Meca; (...); Maurino, Jorge

Meeting Abstract. 2021


Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis

Barreiro-Gonzalez, A; (...); Casanova, B

Meeting Abstract. 2019


Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis.

Mathur D; (...); Marti MB

Article. 10.3389/fneur.2014.00250. 2014


Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018


Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017


Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017


Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016


Potential Biomarkers Associated with Multiple Sclerosis Pathology.

Mathur, Deepali; (...); Casanova, Bonaventura

Article. 10.3390/ijms221910323. 2021


Potential Role of CHI3L1+ Astrocytes in Progression in MS.

Cubas-Núñez L; (...); Casanova B

Article. 10.1212/NXI.0000000000000972. 2021


Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018


Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024


Predictive value of early brain atrophy on response in patients treated with interferon ß.

Pérez-Miralles FC; (...); Montalban X

Article. 10.1212/NXI.0000000000000132. 2015


Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018


PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019


Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

  • Open Access.

Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report

Gil-Perotin, S; (...); Casanova-Estruch, B

Article. 10.3389/fneur.2018.00340. 2018


Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1097/DSS.0000000000001046. 2017


Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018


Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire

Meca-Lallana, JE; (...); Ballesteros, J

Article. 10.1371/journal.pone.0255317. 2021


Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study

Meca-Lallana, J; (...); Maurino, J

Meeting Abstract. 2020


Recambio plasmático terapéutico: aplicaciones en neurología.

Láinez-Andrés JM; (...); Santonja JM

Abstract of Published Item. 10.33588/rn.6003.2014393. 2015


Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Ramo-Tello, Cristina; (...); Rovira À

Article. 10.3390/jpm12010006. 2021


Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

Alcala, C; (...); Casanova, B

Editorial Material. 10.1016/j.msard.2018.12.005. 2019


Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017


Relapsing inflammatory optic neuropathy: clinical description in a serie of 16 patients

Navarro, L.; (...); Casanova, B.

Meeting Abstract. 2014


Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice

Castillo, J; (...); Casanova, B

Meeting Abstract. 2017


Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2022


Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-024-07772-6. 2024


Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)

Fernandez, Oscar; (...); Tintore, Mar

Article. 10.33588/rn.6105.2015228. 2015


Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II)

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.6106.2015239. 2015


Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I)

Fernandez, O; (...); Rodriguez-Antiguedad, A

Review. 10.33588/rn.6501.2017168. 2017


Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II)

Fernandez, Oscar; (...); Rodriguez-Antiguedad, Alfredo

Review. 10.33588/rn.6502.2017169. 2017


Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.5706.2013276. 2013


Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

Fernández Ó; (...); Post-ECTRIMS Group

Article. 10.33588/rn.5707.2013277. 2013


Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.5906.2014321. 2014


Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

Fernandez, Oscar; (...); Rodriguez-Antigueedad, Alfredo

Article. 10.33588/rn.5907.2014334. 2014


Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)

Fernández Ó; (...); Grupo Post-ECTRIMS

Article. 10.33588/rn.5908.2014335. 2014


Revision de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunion Post-ECTRIMS (I).

Fernandez O; (...); Grupo Post-Ectrims GP

Abstract of Published Item. 10.33588/rn.6105.2015228. 2015


Revision de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunion Post-ECTRIMS (II).

Fernandez O; (...); Rodriguez-Antiguedad A

Article. 10.33588/rn.6502.2017169. 2017


Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies

Alcala, C; (...); Casanova, B

Meeting Abstract. 2017


Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018


SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.

Arrambide, Georgina; (...); Meca-Lallana, Jose E

Article. 10.1212/NXI.0000000000001024. 2021


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020


Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017


Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017


Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.

Fissolo, Nicolas; (...); Comabella, Manuel

Article. 10.1136/jnnp-2023-332251. 2023


Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Monreal E; (...); Villar LM

Article. 10.1093/brain/awae260. 2024


Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2023


Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2024


Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis

Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

Pérez-Miralles F; (...); Casanova B

Article. 10.1016/j.msard.2021.102860. 2021


Silent Progression or Bout Onset Progressive Multiple Sclerosis?

Gil-Perotin, S; (...); Casanova, B

Letter. 10.1002/ana.25537. 2019


Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation

Sanchez-Lazaro, I.; (...); Salvador-Sanz, A.

Article. 10.1016/j.healun.2014.01.392. 2014


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


SNPs and taxane toxicity in breast cancer patients

Bosó V; (...); Aliño SF

Article. 10.2217/PGS.14.127. 2014


Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Cantón R; (...); Solé A

Article. 10.1016/j.arbres.2014.09.021. 2015


Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: Real-world results and baseline characteristics of initial patients

Fernandez, O; (...); Sanchez-de la Rosa, R

Meeting Abstract. 2017


Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYA Registry): safety and effectiveness after one year on treatment

Rodriguez-Antigueedad, A.; (...); Fernandez, O.

Article. 2014


Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score

Carratala, S; (...); Estruch, BC

Meeting Abstract. 2018


Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Pérez-Cebrián M; (...); Llopis-González A

Article. 2015


Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.

Balzano T; (...); Felipo V

Article. 10.1186/s12974-020-01746-z. 2020


Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective

Meca-Lallana, J.; (...); Maurino, J.

Meeting Abstract. 2021


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The impact of stigma in people with primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova-Estruch, B

Meeting Abstract. 2018


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

  • Open Access.

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018


Therapeutic plasma exchange: applications in neurology

Lainez-Andres, Jose M.; (...); Santonja, Jose M.

Article. 10.33588/rn.6003.2014393. 2015


Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.

Megías Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.rx.2015.01.008. 2015


Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizan, L; (...); Polanco, C

Review. 10.2147/PPA.S67253. 2014


Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.

Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2023.1060696. 2023


Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.

Landete, Lamberto; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2021.727586. 2021


Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice

Alcala-Vicente, C; (...); Casanova-Estruch, B

Article. 10.33588/rn.6410.2016359. 2017


Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe

Alcala, C; (...); Casanova, B

Meeting Abstract. 2018


Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe

Alcala, C; (...); Casanova, B

Article. 10.1007/s00415-019-09195-2. 2019


Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

García-Robles AA; (...); Poveda JL

Letter. 10.1016/j.jns.2016.04.048. 2016


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


Campos de estudio

Compartir